Avior Wealth Management LLC Lowers Stake in Abbott Laboratories $ABT

Key Points

• Avior Wealth Management cut its Abbott Laboratories stake by 47.5% in the second quarter, selling 19,199 shares and retaining 21,257 shares worth approximately $1.93 million.
• Analysts maintain a generally positive view of Abbott, with a “Moderate Buy” consensus and an average price target of $118.17, although several firms recently lowered their targets.
• Abbott exceeded quarterly earnings and revenue expectations, reporting $1.31 in EPS and $12.59 billion in revenue, while maintaining a quarterly dividend of $0.63 per share, equivalent to a 2.3% yield.

Avior Wealth Management LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 47.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 21,257 shares of the healthcare product maker's stock after selling 19,199 shares during the period. Avior Wealth Management LLC's holdings in Abbott Laboratories were worth $1,929,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABT. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter worth $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories in the 4th quarter worth about $25,000. Purpose Unlimited Inc. acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABT has been the subject of several research reports. Jefferies Financial Group decreased their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Argus reduced their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, April 21st. Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target for the company. Barclays cut their price objective on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research report on Monday, April 20th. Finally, Raymond James Financial reduced their price objective on Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $118.17.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $107.86 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a 50 day moving average of $95.06 and a 200-day moving average of $99.97. The stock has a market cap of $186.63 billion, a P/E ratio of 34.90, a price-to-earnings-growth ratio of 2.05 and a beta of 0.59. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm's revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source